Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100

Blood

Volumn 121, Issue 17, 2013, Pages 3307-3318

  Leonhardt, Franziska ^a   Grundmann, Sebastian ^a   Behe, Martin ^a,b   Bluhm, Franziska ^a   Dumont, Rebecca A ^a,c   Braun, Friederike ^a   Fani, Melpomeni ^a,d   Riesner, Katarina ^e   Prinz, Gabriele ^a   Hechinger, Anne Kathrin ^a   Gerlach, Ulrike V ^a   Dierbach, Heide ^a   Penack, Olaf ^e   Schmitt Gräff, Annette ^a   Finke, Jürgen ^a   Weber, Wolfgang A ^a   Zeiser, Robert ^a,f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ALPHAVBETA5 INTEGRIN; CELL SURFACE RECEPTOR; FIBRONECTIN; MICRORNA 100; TENASCIN; VASCULOTROPIN; VITRONECTIN; VITRONECTIN RECEPTOR; CD51 ANTIGEN; MESSENGER RNA; MICRORNA; MIRN100 MICRORNA, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BONE MARROW DERIVED DENDRITIC CELL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIUM CELL; ENTERITIS; GENE EXPRESSION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE TISSUE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; ENTEROPATHY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; GENETICS; GRAFT VERSUS HOST REACTION; INFLAMMATION; LUMINESCENCE; MALE; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTEGRIN ALPHAV; INTESTINAL DISEASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MLCS; MLOWN;

EID: 84879370407     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-442665     Document Type: Article

References (52)

1. Naldini A, Leali D, Pucci A, et al. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 2006;177(7):4267-4270.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
3. Penack O, Henke E, Suh D, et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst. 2010;102(12):894-908.
4. Penack O, Socié G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood. 2011;117(16):4181-4189.
5. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674): 1550-1561.
6. Wilhelm K, Ganesan J, Müller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12): 1434-1438.
7. Tsukamoto H, Chernogorova P, Ayata K, et al. Deficiency of CD73/ecto-59-nucleotidase in mice enhances acute graft-versus-host disease. Blood. 2012;119(19):4554-4564.
8. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118(5): 1359-1369.
9. Zeng L, Yan Z, Ding S, et al. Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice. Transplant Proc. 2008; 40(8):2670-2673.
10. Takatsuka H, Wakae T, Mori A, et al. Effects of total body irradiation on the vascular endothelium. Clin Transplant. 2002;16(5):374-377.
11. Barilli A, Visigalli R, Sala R, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res. 2008;78(3):563-571.
12. Lau DC, Wong KL, Hwang WS. Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int. 1989;35(2):604-613.
13. Grundmann S, Hans FP, Kinniry S, et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation. 2011;123(9):999-1009.
14. Chamorro-Jorganes A, Araldi E, Penalva LO, et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol. 2011;31(11):2595-2606.
15. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350-355.
16. van Mil A, Grundmann S, Goumans MJ, et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res. 2012;93(4):655-665.
17. Chen JJ, Zhou SH. Mesenchymal stem cells overexpressing MiR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiol J. 2011;18(6):675-681.
18. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103(9): 1227-1230.
19. Germain S, Monnot C, Muller L, et al. Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding. Curr Opin Hematol. 2010;17(3):245-251.
20. Contois L, Akalu A, Brooks PC. Integrins as “functional hubs” in the regulation of pathological angiogenesis. Semin Cancer Biol. 2009;19(5): 318-328.
21. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008; 111(5):2919-2928.
22. Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26(7):1617-1629.
23. Kaplan DH, Anderson BE, McNiff JM, et al. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9):5467-5475.
24. Dudda JC, Lembo A, Bachtanian E, et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol. 2005;35(4): 1056-1065.
25. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD41CD251 regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108(1):390-399.
26. Cheng C, Komljenovic D, Pan L, et al. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med. 2011;14(1):15-20.
27. Dumont RA, Deininger F, Haubner R, et al. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of a(n)b(3) integrin expression and facile radiosynthesis. J Nucl Med. 2011;52(8):1276-1284.
28. Goodman SL, Hölzemann G, Sulyok GA, et al. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem. 2002;45(5):1045-1051.
29. Haraldsen G, Rugtveit J, Kvale D, et al. Isolation and longterm culture of human intestinal microvascular endothelial cells. Gut. 1995;37(2): 225-234.
30. Rosenberger C, Heyman SN, Rosen S, et al. Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int. 2005;67(2): 531-542.
31. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001;48(1):151-157.
32. Adair TH, Gay WJ, Montani JP. Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am J Physiol. 1990;259(3 pt 2): R393-R404.
33. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
34. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588-4598.
35. Marks R, Potthoff K, Hahn J, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112(2):415-425.
36. Grüllich C, Bertz H, Spyridonidis A, et al. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant. 2008; 41(10):845-850.
37. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012;106(1): 147-153.
38. Liang Y, Liu C, Djeu JY, et al. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood. 2008;111(2): 954-962.
39. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006; 107(4):1703-1711.
40. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2005;17(3):293-298.
41. Allen DB, Maguire JJ, Mahdavian M, et al. Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Arch Surg. 1997;132(9): 991-996.
42. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum. 1970;13(6):769-776.
43. Peters CL, Morris CJ, Mapp PI, et al. The transcription factors hypoxia-inducible factor 1a and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004;50(1):291-296.
44. Ninikoski J, Heughan C, Hunt TK. Oxygen and carbon dioxide tensions in experimental wounds. Surg Gynecol Obstet. 1971;133(6):1003-1007.
45. Ozawa K, Kondo T, Hori O, et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest. 2001; 108(1):41-50.
46. Asosingh K, Swaidani S, Aronica M, et al. Th1- and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol. 2007;178(10):6482-6494.
47. Silverman MD, Haas CS, Rad AM, et al. The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum. 2007;56(6):1817-1826.
48. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest. 1999;103(1):3-4.
49. Szekanecz Z, Besenyei T, Paragh G, et al. Angiogenesis in rheumatoid arthritis. Autoimmunity. 2009;42(7):563-573.
50. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008;173(1):265-277.
51. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2007;56(6): 855-862.
52. Acharya M, Mukhopadhyay S, Païdassi H, et al. av Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J Clin Invest. 2010;120(12):4445-4452.